
    
      Patients that have recurrent glioblastoma that has progressed on bevacizumab continue to
      receive bevacizumab with the addition of Tumor Treating Fields Therapy. Treatment is given
      until disease progression or the development of adverse events that require complete
      discontinuation.
    
  